Serum transforming growth factor beta 1 levels in multiple myeloma patientsHasan Şenol Coşkun1, Osman İlhan2, Muhit Özcan2, Selime Ayaz3, Klara Dalva2, Celalettin Üstün2, Mutlu Arat2
1Department Of Medical Oncology, Süleyman Demirel University School Of Medicine, Isparta, Turkey
2Department Of Haematology, Ankara University School Of Medicine, Ankara, Turkey
3Haematology Laboratory, Yüksek İhtisas Hospital, Ankara, Turkey
Cytokinesis plays an important role in the etiology of multiple myeloma. The transforming growth factor (TGF) beta 1 levels in 82 sera from 60 patients with multiple myeloma were analyzed by ELISA. Fourty one sample were obtained before treatment from newly diagnosed patients, 22 after treatment from the same patients and 19 from relapsed/refractory patients. Serum median TGF level of newly diagnosed patients was 769.5 ng/mL (126-1853), and the relapsed/refractory patients had similar levels. TGF levels after chemotherapy were not different between patients that reached plateau phase and those who remained refractory. We found a negative correlation between TGF and C-reactive protein and blood urea nitrogen and a positive correlation between TGF and hemoglobin level in newly diagnosed patients. After treatment, it was determined that TGF levels at diagnosis were higher in patients who reached plateau phase than in the refractory patients. Elevated serum TGF concentration at diagnosis in multiple myeloma patients may be a favorable predictor of response. Keywords: Multiple myeloma, TGF-beta, Survival.
Multipl miyeloma hastalarında serum transforming growth faktör beta 1 seviyesiHasan Şenol Coşkun1, Osman İlhan2, Muhit Özcan2, Selime Ayaz3, Klara Dalva2, Celalettin Üstün2, Mutlu Arat2
1Department Of Medical Oncology, Süleyman Demirel University School Of Medicine, Isparta
2Department Of Haematology, Ankara University School Of Medicine, Ankara
3Haematology Laboratory, Yüksek İhtisas Hospital, Ankara
Sitokinler multipl miyeloma etyolojisinde önemli bir rol oynar. Altmış hastadan elde edilen 82 örnekte serum transforming growth faktör (TGF) beta 1 seviyesi çalışıldı. Kırkbir örnek yeni tanı konulan hastalardan tedavi öncesi, 22 örnek tedaviden sonra, 19 örnek ise refrakter relaps hastalardan elde edildi. Yeni tanı konulan hastalarda tedavi uygulama öncesi ortanca serum TGF seviyesi 769.5 ng/mL (126-1853) bulundu. Bu değer relaps ve refrakter hastalarla benzerdi. Kemoterapi sonrası TGF seviyeleri plato safhasına ulaşan veya refrakter kalan hastalarda farklı değildi. Yeni tanı hastalarda TGF ile C-reaktif protein ve kan üre nitrojeni negatif korelasyon, hemoglobin ile pozitif korelasyon bulundu. Tanı anında TGF seviyesi kemoterapi ile plato safhasına ulaşan hastalarda refrakter kalan hastalardan daha yüksekti. Multipl miyelomada tanı anında yüksek serum TGFbeta seviyeleri iyi cevabın bir göstergesi olabilir. Anahtar Kelimeler: Multipl miyeloma, TGF-beta, Sağkalım.
Hasan Şenol Coşkun, Osman İlhan, Muhit Özcan, Selime Ayaz, Klara Dalva, Celalettin Üstün, Mutlu Arat. Serum transforming growth factor beta 1 levels in multiple myeloma patients. Turk J Hematol. 2006; 23(1): 47-52
Corresponding Author: Hasan Şenol Coşkun, Türkiye |
|